4142:TPE
Adimmune Corp
16,70 TWD
arrow_upward
+0,60%(+0,10) 1 д.
12.11, 13:30:32 ч. Гринуич+8 · TWD
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за 4142…
Отваряне
16,55 TWD
Висока
16,90 TWD
Ниска
16,55 TWD
Пазарна кап.
7,17 млрд.
Ср. обем
1,14 млн.
Обем
483,07 хил.
Най-висока цена за 52 седм.
22,50 TWD
Най-ниска цена за 52 седм.
15,65 TWD
EPS
-0,34 TWD
Акции в обращение
235,29 млн.
Брой служители
564
Отваряне
16,55 TWD
Висока
16,90 TWD
Ниска
16,55 TWD
Пазарна кап.
7,17 млрд.
Ср. обем
1,14 млн.
Обем
483,07 хил.
Най-висока цена за 52 седм.
22,50 TWD
Най-ниска цена за 52 седм.
15,65 TWD
EPS
-0,34 TWD
Акции в обращение
235,29 млн.
Брой служители
564
Новинарски материали
От източници в мрежата и новинарски партньори
Freedom Broker
·
преди 19 часа
S&P 500 и Nasdaq Composite растут после отчёта CoreWeave
Infostock
·
преди 21 часа
Какво предстои за S&P 500 през 2027 година?
TradingView
·
преди 1 час
Stock Market Today: Nvidia Rout Sinks Nasdaq, S&P 500 Futures as Board Weighs Jensen Huang’s Future — CRWV, TTEK, FNV in Focus
Yahoo Finance
·
преди 53 минути
What SPDR S&P 500 ETF (SPY) Bought: Apple Leads on Nov. 10
Профил
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Всичко за Adimmune Corp
Главен изпълнителен директор-
Служители564
Дата на основаване1965
Централен офис-
БраншHealth Care
Индустрия-
Уебсайтadimmune.com.tw